Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun 21;13(23):3176-82.
doi: 10.3748/wjg.v13.i23.3176.

Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma

Affiliations

Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma

Gassimou Bangoura et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma (HCC).

Methods: Surgical specimens from 315 patients with HCC as well as 196 adjacent noncancerous lesions and 22 cases of normal liver tissue were investigated by immunohistochemistry (IHC) for HIF-2alpha/EPAS1 using a standard detection system. Correlations with clinicopathological factors, VEGF, microvessel density (MVD), and prognosis were analyzed.

Results: Immunoreactivity of HIF-2alpha/EPAS1 was positive in 69.5% of HCC, 55.6% of adjacent noncancerous tissue, and 0% of normal liver tissue. And it was significantly correlated with tumor grade, venous invasion, intrahepatic metastasis, necrosis, and capsule infiltration. Correlation analysis of HIF-2alpha/EPAS1 with angiogenic factor VEGF (P<0.001), and MVD (P=0.016) was also noted. HIF-2alpha/EPAS1 protein was less frequently expressed in low MVD cases, whereas a high rate of expression was noted in cases with both medium and high MVD (P=0.042). By Kaplan-Meier analysis, strong HIF-2alpha/EPAS1 staining (>50% of tumor cells) in HCC correlated with a shortened survival in patients (Cox's regression, P<0.001, r=3.699).

Conclusion: We conclude that HIF-2alpha/EPAS1 expression may play an important role in tumor progression and prognosis of HCC. Assessment of HIF-2alpha/EPAS1 expression in HCC may be used as a diagnostic tool and possibly a target in the treatment of HCC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative examples of immunohistochemical staining for HIF-2α/EPASE1, VEGF, and CD31 in HCC. A: Strong cytoplasmic immunore-activity of HIF-2α/EPASE1 is observed in cancers cells (× 400). B: Strong staining in the cytoplasm of noncancerous cirrhotic tissue (× 400). C: HIF-2α/EPAS1-positive staining in perinecrotic area (N) and D: In the cytoplasm of macrophages (× 400). E: Parallel studies of VEGF protein (cytoplasmic staining) and F: CD31 (for microvessels) immunohistochemistry performed on HCC (× 200).
Figure 2
Figure 2
The overall 7-year survival curves of patients with positive HIF-2α/EPAS1 and negative HIF-2α/EPAS1 are shown for the entire cohort, P = 0.003 (A), as well as patients with venous invasion and without venous invasion, P = 0.014 (B).

References

    1. Nagao Y, Tanaka K, Kobayashi K, Kumashiro R, Sata M. A cohort study of chronic liver disease in an HCV hyperendemic area of Japan: a prospective analysis for 12 years. Int J Mol Med. 2004;13:257–265. - PubMed
    1. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer. 1985;51:713–726. - PMC - PubMed
    1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–1133. - PubMed
    1. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177–182. - PubMed
    1. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943. - PubMed

Publication types

Substances